Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Professor of Orthopaedic and Tropical Surgery and Consultant Orthopaedic and Spine Surgeon Chris Lavy has been awarded a prestigious honorary fellowship by the British Orthopaedic Association (BOA).

Photo of Chris Lavy

An Honorary Fellowship is the highest honour that the BOA offer, and is awarded to individuals who have made outstanding contributions to trauma and orthopaedics.

Professor Lavy's clinical interests include surgery of the spine, hip and knee, and his research interests focus on surgery in Africa and the Tropics. He leads the NDORMS Lavy Global Surgery group which is deeply involved in research, teaching and training to strengthen surgical care and training capacity in Africa. This includes SURG-AFRICA, which is focused on scaling up safe surgery in district hospitals to make it accessible to otherwise neglected rural populations, and clubfoot training and research to help to improve treatment for children born with clubfoot in Africa.

One of his newest emerging areas of research is into treatments that could improve the recovery rate from spinal cord injuries.

Candidates for Honorary Fellowships are considered annually by a Board comprising the last five BOA Presidents and usually presented to recipients by the President at the annual BOA Congress.

Due to the coronavirus pandemic, Prof Lavy was presented with the award virtually at this year's BOA conference, and will receive the award in person at the BOA Congress in Aberdeen next September.

Similar stories

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

Patients like me

What can patients learn from the experiences of people like them who’ve already had a hip replacement? A new tool called ‘Patients like me’ helps answer some of the questions about pain, complications and how long the prosthesis might last.

Study reveals new evidence on rare blood-clotting condition after covid-19 vaccination

Researchers from NDORMS at the University of Oxford have investigated claims that some adenovirus-based COVID-19 vaccines increase the risk of rare blood clots compared to their mRNA-based counterparts.

NDORMS contributes to new UK research to tackle monkeypox outbreak

The UK’s efforts to tackle the monkeypox outbreak will receive a huge boost with the creation of a new research consortium and a new study to study vaccine effectiveness.

World Osteoporosis Day 2022

A bone-healthy lifestyle is vital for strong bones and a mobile, fracture-free future. On World Osteoporosis Day, we are sharing advice from the International Osteoporosis Foundation (IOF), on putting your bone health first.

Mathematician boosts data science research at the Kennedy Institute

Welcome to Yang Luo who has joined the Kennedy Institute as the Principal Investigator of the Luo Group. Her lab is leading the investigation into how genetic variations contribute to diseases of the immune system.